ABUS vs TLRY · P/E 5.4, rev $6.2M vs rev $821.3M
Arbutus Biopharma Corp (ABUS) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported TLRY revenue for 2025-05-31 was $821.3M. Net income was -$2.18B. Revenue was up 4.1% from 2024-05-31 to 2025-05-31. TLRY currently screens at market cap $573.9M.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the ABUS and TLRY stock pages for the full models.
Not investment advice.